With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.
To a solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6- isoquinolinecarboxylic acid (0.1 1 g, 0.4 mmol), HOBt (55 mg, 0.4 mmol), EDCI (77 mg, 0.4 mmol) and triethylamine (140 mul, 1 mmol) in DCM (5 ml.) was added 2-[(4- chlorophenyl)methyl]-4-methyl-1 ,3-thiazol-5-amine hydrochloride (80 mg, 0.33 mmol) and the resulting mixture was stirred at room temperature for 5 days. The organic phase was washed successively with a 1 N solution of hydrochloric acid, with a 1 N solution of sodium hydroxide, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM / EtOAc: 8 / 2 to give the title compound as a yellow oil (25 mg, 15%). LC/MS: m/z 498 (M+H)+, Rt : 3.83 min.
#N/A
Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2009/150196; (2009); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem